Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
02/16/18Seattle Genetics Announces Expiration of Hart-Scott-Rodino Waiting Period
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 16, 2018-- Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) with respect to Seattle Genetics’ proposed acquisition of Cascadian Therapeutics, Inc. (NASDAQ:CASC) expired at 11:59 p.m. on February 15, 2018. The expiration of the HSR Act waiting period satisfies one of the conditions to consummate the tend... 
Printer Friendly Version
02/09/18Seattle Genetics and Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration
-Companies to Evaluate Novel Bispecific Immuno-Oncology Agents that Combine Pieris’ Anticalin Technology with Select Seattle Genetics Cancer-Targeted Antibodies- BOSTON & BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 9, 2018-- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, and Seatt... 
Printer Friendly Version
02/08/18Seattle Genetics Commences Tender Offer for Cascadian Therapeutics, Inc.
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 8, 2018-- Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that its wholly-owned subsidiary, Valley Acquisition Sub, Inc., has commenced its previously announced tender offer for all outstanding shares of common stock of Cascadian Therapeutics, Inc. (NASDAQ:CASC) at a price of $10.00 per share net to the seller in cash, without interest, less any applicable withholding taxes (the “Offer”). The Offer is being made... 
Printer Friendly Version
02/06/18Seattle Genetics Reports Fourth Quarter and Year 2017 Financial Results
-Record ADCETRIS® (Brentuximab Vedotin) Net Sales in U.S. and Canada of $307.6 Million in 2017, Including $83.7 Million in the Fourth Quarter- -ECHELON-1 Supplemental BLA for ADCETRIS in Combination with Chemotherapy for Frontline Advanced Classical Hodgkin Lymphoma Granted FDA Priority Review and PDUFA Action Date of May 1, 2018- -ECHELON-2 Data Expected in 2018- -Proposed Acquisition of Cascadian Therapeutics Would Add Th... 
Printer Friendly Version
02/02/18Seattle Genetics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 2, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that the underwriters of its previously announced underwritten public offering have exercised in full their option to purchase an additional 1,730,769 shares of Seattle Genetics’ common stock. Including this option exercise, total gross proceeds to Seattle Genetics from the offering of an aggregate of 13,269,230 shares at a price to the public of $52.00 ... 
Printer Friendly Version
02/01/18Seattle Genetics Announces Pricing of Public Offering of Common Stock
BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 1, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the pricing of an underwritten public offering of 11,538,461 shares of its common stock at a price to the public of $52.00 per share. All of the shares are being sold by Seattle Genetics. The gross proceeds to Seattle Genetics from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approxim... 
Printer Friendly Version
01/31/18Seattle Genetics Announces Proposed Public Offering of Common Stock
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 31, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that it has commenced an underwritten public offering of $550.0 million of shares of its common stock. All of the shares are being offered by Seattle Genetics. In addition, Seattle Genetics expects to grant the underwriters of the offering a 30-day option to purchase up to an additional $82.5 million of shares of its common stock solely to cover ... 
Printer Friendly Version
01/31/18Seattle Genetics to Acquire Cascadian Therapeutics, Adding Late-Stage Breast Cancer Program to Its Oncology Pipeline
-Enhances Seattle Genetics’ Portfolio of Solid Tumor Programs with Potential Rapid Registrational Pathways- -Provides Global Rights to Pivotal Phase 2 Program in Development for HER2-Positive Metastatic Breast Cancer- -Conference Call Today at 8:30 a.m. ET- BOTHELL, Wash. & SEATTLE--(BUSINESS WIRE)--Jan. 31, 2018-- Seattle Genetics, Inc. (Nasdaq:SGEN) and Cascadian Therapeutics, Inc. (Nasdaq:CASC) today announced the... 
Printer Friendly Version
01/22/18Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Receives European Commission Approval for CD30-Positive Cutaneous T-Cell Lymphoma after at Least One Prior Systemic Therapy
Approval Based on Positive Phase 3 ALCANZA Trial Results, which Demonstrated a Highly Statistically Significant Improvement in Rate of Objective Response Lasting at Least Four Months, Median Progression-Free Survival, and Improvement in Symptom Burden in ADCETRIS Arm BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 22, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) reported today that its collaborator, Takeda Pharmaceutical Company Limited, announced that ... 
Printer Friendly Version
01/18/18Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2017 Financial Results on February 6, 2018
BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 18, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and year 2017 financial results on Tuesday, February 6, 2018 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: ... 
Printer Friendly Version
01/08/18Seattle Genetics Highlights Leadership in Expanding Field of Antibody-Drug Conjugates (ADCs) at the 36th Annual J.P. Morgan Healthcare Conference
-Continued Progress In Establishing ADCETRIS® (brentuximab vedotin) as the Foundation of Care for CD30-Expressing Lymphomas- -Two Solid Tumor ADC Programs Advancing Under Accelerated Approval Pathways- -Multiple Collaborator ADC Programs in Late-Stage Trials for Range of Tumor Types- BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 8, 2018-- Seattle Genetics, Inc. (NASDAQ: SGEN) highlighted today the progress of its pipeline... 
Printer Friendly Version
01/02/18FDA Accepts Supplemental Biologics License Application and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma
-PDUFA Action Date May 1, 2018- -Submission Based on Positive Results from the Phase 3 ECHELON-1 Clinical Trial- -FDA Previously Granted Breakthrough Therapy Designation for ADCETRIS in Frontline Advanced Hodgkin Lymphoma- BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 2, 2018-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental Biolo... 
Printer Friendly Version